Reply  by Al-Omran, Mohammed & Mamdani, Muhammad M.
JOURNAL OF VASCULAR SURGERY
Volume 49, Number 6 Letters to the Editor 1633of Tregs in many solid tumors correlate inversely with patient surviv-
al.5 Moreover, the elderly have depressed immune functions6 and are
more likely than younger subjects to harbormicroscopic foci of cancer
cells. Therefore, further impairment of immune function in the elderly
likely increases the chance of occult tumor growth.
Importantly, statin trials have largely excluded subjects with
prevalent or remote cancer. In practice, elderly patients are treated
with statins regardless of cancer status. It is quite possible that in the
routine treatment of elderly subjects with statins, an increase cancer
incidence and mortality may exceed in magnitude any decrease in
cardiovascular disease morbidity and mortality. Perhaps suboptimal
use of statin therapy in the elderly is actually a blessing in disguise.
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Reply
In response to the letter to the editor by Dr Mark R. Gold-
stein, et al, entitled “Might suboptimal use of statin therapy in the
elderly be a blessing in disguise?,” the authors pointed out that
suboptimal use of statin might do more harm than good in the
elderly because of the increased risk of cancer in these patients.
However, the association between statin use and the development
and/or prevention of cancer has been conflicting.
Although at the experimental level, statins have been demon-
strated to contribute to the development of cancer by acting as
immunoregulators, other studies have shown that statins could trig-
ger cells of certain tumor types to undergo apoptosis,1 which may be
thebasis for the inhibitory effect of statins on cancer cell proliferation.2
In 2002, the PROspective Study of Pravastatin in the Elderly
at Risk (PROSPER) suggested an increased incidence of cancer
diagnosed during the treatment period of 3.2 years (245 [8.5%] in
pravastatin group vs 199 [6.8%] placebo group, P  .02).3 How-ever, these findings have not been replicated consistently in subse-
quent large clinical trials and thus may be attributable to chance
findings. Indeed the Heart Protection Study, the largest clinical trial
to study the benefits of statins in over 20,000 high-risk individuals,
conclusively demonstrated their benefits among a broad population,
including the elderly, without an increased risk for cancer.4
Further, other studies have suggested a large protective effect
of statins on certain cancers in the elderly population. A large
population-based study compared 25,594 non-statin users’ pa-
tients to 37,248 patients using statins showed that statin users had
a statistically significant lower risk for total cancer than nonusers
after adjustment for age (hazard ratio [HR]  0.76, 95% confi-
dence interval [CI]  0.73 to 0.80) and multiple potential con-
founders (HR  0.74, 95% CI  0.70 to 0.78).5
Other studies have suggested a neutral effect of statins on
cancers. A recently published meta-analysis of 20 trials studied
patients treated with statins found that statins have a neutral effect
on cancer and cancer death risks (odds ratio [OR], 1.02; 95% CI,
0.97-1.07) and (OR, 1.01; 95% CI, 0.93-1.09), respectively.6
In conclusion, the currently available evidence consistently
demonstrates significant cardiovascular benefit for statins without
significant harm. An association between statins and cancer has not
been firmly established and cannot be based on the findings of a
single trial. Without conclusive evidence from additional observa-
tional studies and randomized trials that examine the association
between statins and cancer (causation, prevention, or neutral ef-
fect), statin use for the primary and secondary prevention of
cardiovascular adverse events should be continued in the elderly
patients in a similar way as in the younger population.
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